Frontiers in Diabetic Macular Edema: Durable Suppression for Addressing Health Disparities

Frontiers in Diabetic Macular Edema: Durable Suppression for Addressing Health Disparities

ReachMD Healthcare Image
RestartResume

Can we improve outcomes in DME by going beyond VEGF inhibition? Join us to learn about novel targets, their mechanisms, and the latest clinical data.

  • Overview

    Diabetic macular edema (DME) remains undertreated in the real world. New targeted agents are in development for DME that seek to broaden current treatment approaches while improving upon the durability of VEGF suppression. These new treatments that go beyond the current standard of care may help reduce treatment burdens and ultimately improve vision outcomes in DME. Join our two experts, Dr. Christina Weng and Dr. Arshad Khanani, as they discuss these emerging agents, their mechanisms of action, and the latest available data.

Facebook Comments

Register

We’re glad to see you’re enjoying Prova Education…
but how about a more personalized experience?

Register for free